|
|
|
| The application effect of Perindopril in patients with coronary heart disease after percutaneous coronary interventions and its influence on neurohormone and endothelial function |
| ZHOU Xiaoming1 DENG Guiming2 TAN Qi1▲ |
1.Department of Cardiology, the First Hospital of Hu′nan University of Chinese Medicine, Hu′nan Province, Changsha 410007, China;
2.Department of Scientific Research, the First Hospital of Hu′nan University of Chinese Medicine, Hu′nan Province, Changsha 410007, China |
|
|
|
Abstract Objective To observe the application effect of Perindopril in patients with coronary heart disease after percutaneous coronary interventions, and analyze its influence on neurohormone and endothelial function. Method From December 2013 to December 2017, 120 cases with coronary heart disease who underwent percutaneous coronary interventions in the First Hospital of Hu′nan University of Chinese Medicine were selected. They were divided into the control group (60 cases) and the observation group (60 cases), according to different treatment regimens. The control group was received routine basic treatment and percutaneous coronary intervention according to their condition, and the observation group was received Perindopril Tablets orally on the basis of treatment in the control group. The course of treatment was 3 months. The neurohormone, endothelial function and cardiac function indexes before and after treatment of the two groups were compared and the incidence of ischemic events 1 year after operation was recorded in both groups. Results Before treatment, there was no statistically significant difference in angiotensin Ⅱ (Ang Ⅱ), aldosterone (ALD) and atrial natriuretic peptide (ANP) level of the two groups (P > 0.05). After treatment, Ang Ⅱ, ALD and ANP levels of the two groups were lower than those before treatment, and the observation group was lower than the control group, and the differences were statistically significant (all P < 0.05). Before treatment, there was no significant difference in the endothelial progenitor cells (EPCs), nitric oxide (NO) and endothelin-1 (ET-1) level between the two groups (P > 0.05). After treatment, the EPCs and NO levels in the two groups were higher than those before treatment, and the levels of ET-1 were lower than before treatment, and the EPCs and NO levels in the observation group were higher than those in the control group, the levels of ET-1 were lower than those in the control group, with statistically significant differences (all P < 0.05). Before treatment, there was no statistically significant difference in left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV) and left ventricular ejection fraction (LVEF) level between the two groups (P > 0.05). After treatment, LVEDV and LVESV levels in the two groups were lower than those before treatment, and LVEF levels were higher than those before treatment. LVEDV and LVESV levels in the observation groups were lower than those in the control group, and LVEF levels were higher than those in the control group, with statistically significant differences (all P < 0.05). The incidence of ischemic events 1 year after operation in the observation group was significantly lower than that in the control group, with statistically significant differences (P < 0.05). Conclusion Perindopril can effectively improve the level of neurohormone and endothelial injury after percutaneous coronary intervention in patients with coronary heart disease, improve the pumping function of the heart, and reduce the occurrence of postoperative clinical ischemic events.
|
|
|
|
|
|
[1] 司佳卉，孟若谷，余灿清，等.疾病家族史与冠心病发生风险的关联研究[J].中华流行病学杂志，2018，39（2）：173-178.
[2] 龚敏，赵翰文.冠状动脉介入对急性心肌梗死患者血浆脑钠肽水平及心室重塑的影响[J].实用临床医药杂志，2017，21（13）：189-190.
[3] Cheng J，Zhang W，Zhang X，et al. Effect of angiotensin-con-verting enzyme inhibitors andangiotensin Ⅱ receptor blockers on all-cause mortality，cardiovascular deaths，and cardiovascular events in patients with diabetes mellitus：a meta-analysis [J]. JAMA Intern Med，2014，174（5）：773-785.
[4] 韩雅玲.中国经皮冠状动脉介入治疗指南（2016）解读[J].中国循环杂志，2016，31（z2）：5-8.
[5] 吴天源，李韶南，罗义，等.血清醛固酮对冠心病患者介入术后心血管事件和支架内再狭窄的预测价值[J].实用医学杂志，2018，34（2）：227-230.
[6] 朱勇，张美春，高孟秋，等.替格瑞洛与氯吡格雷对冠心病患者冠状动脉介入术后炎症因子的影响[J].中国临床药理学杂志，2016，32（14）：1257-1260.
[7] Wang J，Liu JH，Zhu XL，et al. Nonculpfit lesion progression inpatients with ST elevation myocardial infarction after primary percutaneous coronary intervention [J]. Int Heart J，2014，55（1）：48-52.
[8] 郭军，皇甫丰田，唐龙骞，等.某院门诊高血压合并冠心病患者应用ACEI/ARB类药物的相关因素研究[J].中国药房，2017，28（23）：3201-3203.
[9] 朱小芬.合并冠心病对高血压患者血清醛固酮、血管紧张素水平的影响分析[J].贵州医药，2017，41（5）：481-482.
[10] Zhang WW，Zheng RH，Bai F，et al. Steroidogenic acute regulatory protein/aldosterone synthase mediates angiotensin Ⅱ-induced cardiac fibrosis and hypertrophy [J]. Mol Biol Rep，2020，47（2）：1207-1222.
[11] Lebedeva A，Maryukhnich E，Grivel JC，et al. Productive Cytomegalovirus Infection Is Associated With Impaired Endothelial Function in ST-Elevation Myocardial Infarction [J]. Am J Med，2020，133（1）：133-142.
[12] 王一锦，钟钟，李军农，等.介入治疗联合降血清同型半胱氨酸治疗对冠心病患者血清微炎症介质水平的影响观察[J].血栓与止血，2019，25（2）：246-247.
[13] 廖梦阳，袁璟，廖玉华.开启心力衰竭治疗的新纪元—3类神经激素拮抗剂的应用[J].临床心血管病杂志，2019， 35（7）：583-585.
[14] 曹雪梅，付晓荣.两种剂量培哚普利治疗冠心病的临床效果比较[J].医学临床研究，2016，33（3）：586-588.
[15] 张克军，陶涛，石雪，等.阿魏酸哌嗪分散片联合培哚普利治疗冠心病患者的效果研究[J].山西医药杂志，2018， 47（21）：2567-2569.
[16] 熊少威.不同剂量培哚普利治疗冠心病的临床效果观察[J].中国医药科学，2018，8（8）：52-54.
[17] 鲁成，刘永明，陈启松，等.心脏彩色多普勒评价腹主动脉缩窄大鼠心脏功能及潜阳合剂的干预作用[J].中国医药导报，2018，15（18）：12-15.
[18] 谈红，王雪，李晓燕，等.培哚普利对冠心病患者循环血内皮祖细胞及血管内皮功能的影响[J].中国循环杂志，2015，30（1）：22-25.
[19] 李广运.培哚普利联合瑞舒伐他汀治疗冠心病的疗效及对血管内皮功能与血小板活化功能的影响[J].中西医结合心脑血管病杂志，2018，16（1）：70-73.
[20] ?覶etin M，Erdo■an T，K?覦r?覦■ T，et a1. Endothelial dysfunction，subclinical atherosclerosis and LDL cholesterol are the independent predictors of left atrial functions in hypertension [J]. Int J Cardiovasc Imaging，2020，36（1）：69-77.
[21] 王勇，靳利艳，王留义，等.不同剂量培哚普利对原发性高血压病患者血管内皮功能及血压变异性的影响研究[J].中国全科医学，2016，19（26）：3160-3164.
[22] 张祖峰，王晓红，郝晓慧，等.3种血管紧张素转换酶抑制药对急性心肌梗死患者心室重构的改善作用[J].中国药房，2018，29（4）：526-530. |
|
|
|
